Kyntra Bio
Update in progressKYNB (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Kyntra Bio, Inc. is a San Francisco–based biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for serious unmet medical needs. It is developing FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and other cancers. It is also advancing Roxadustat, a HIF prolyl hydroxylase inhibitor, with Phase III programs for anemia in CKD and myelodysplastic syndromes. It collaborates with Astellas and AstraZeneca. Formerly FibroGen, Inc., renamed in January 2026. Established 1993.
Company score
- Sentiment
- 0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!